Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628984 | 0.82 | MEN1 (0.80) | KMT2AMEN1MAPTNPSR1L3MBTL1 | |
| SCHEMBL4629419 | 0.80 | SCN5A (0.85) | KMT2AL3MBTL1SCN5ASCN2ASMN1; SMN2 | |
| SCHEMBL4629003 | 0.80 | MEN1 (1.00) | KMT2AMEN1MAPTNPSR1L3MBTL1 | |
| SCHEMBL4628422 | 0.78 | MAPT (0.71) | KMT2AMEN1MAPTNPSR1L3MBTL1 | |
| SCHEMBL4628754 | 0.76 | MEN1 (0.67) | KMT2AMEN1MAPTNPSR1L3MBTL1 | |
| SCHEMBL4628492 | 0.76 | SCN5A (1.00) | L3MBTL1SCN5ASCN2ASMN1; SMN2LMNA | |
| SCHEMBL4628823 | 0.75 | MAPT (0.66) | KMT2AMEN1MAPTNPSR1L3MBTL1 | |
| SCHEMBL4628726 | 0.75 | SCN5A (0.66) | KMT2AMEN1MAPTNPSR1SCN5A | |
| SCHEMBL11843383 | 0.74 | MEN1 (0.52) | KMT2AMEN1PTGS2ABCG2SMN1; SMN2 | |
| SCHEMBL4164367 | 0.71 | KMT2A (0.67) | KMT2AMEN1MAPTPTGS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | claimed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | KMT2A 3245/4885MEN1 1819/4885MAPT 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.